Posted by Michael Wonder on 06 May 2021
Preliminary NICE 'no' for Merck's Bavencio
6 May 2021 - NICE has issued a preliminary rejection of NHS funds for use of Merck Serono's Bavencio (avelumab) as maintenance treatment of locally advanced or metastatic urothelial cancer.
Currently, there are no maintenance treatments routinely available for locally advanced or metastatic urothelial cancer that has responded to platinum-based chemotherapy.
